inclusion body myositis

Showing 1 posts of 1 posts found.

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024
Research and Development Abcuro, Musculo-skeletal disorder, ibm, inclusion body myositis, ulviprubart

Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …

The Gateway to Local Adoption Series

Latest content